By Fineline Cube The Standing Committee of the National People’s Congress (NPC) voted to pass the Medical Security Law of the People’s Republic of China at its 24th Session, marking a landmark legislative step for China‘s healthcare system. Comprising 7 chapters and 56 articles, the law will take effect on 1 January 2027, codifying the architecture of medical insurance funds, services, centralized procurement, and supervision into a single statutory framework.
Legislative Milestone
| Item | Detail |
|---|---|
| Enacting Body | Standing Committee of the 14th National People’s Congress (24th Session) |
| Legislation | Medical Security Law of the People’s Republic of China |
| Vote Date | 28 Aug 2026 |
| Effective Date | 1 Jan 2027 |
| Structure | 7 chapters, 56 articles |
| Scope | Medical security system, funds, services, supervision & management |
Core Provisions & Policy Framework
- Guiding Principles: Universal coverage, urban–rural coordination, fairness and uniformity, security and standardization, multi‑tiered protection, and sustainability — with benefit levels commensurate with economic and social development
- Multi‑Tier System: A universal medical security framework with basic medical insurance as the mainstay, alongside maternity insurance, supplementary major medical expense coverage for employees, critical illness insurance for residents, enterprise supplemental insurance, and medical assistance
- Third‑Payer Expansion: Encourages development of commercial health insurance, charitable donations linked to medical security, and mutual medical aid
- Fund Governance: Rules on management, risk control, and payment scope of medical insurance funds; establishes an improved centralized procurement system for pharmaceuticals and medical consumables, with diversified, composite payment methods
- Service Modernization: Public medical security service system with full urban–rural coverage; collective negotiation mechanism; service agreements with qualified medical institutions and pharmaceutical retailers; direct and online real‑time settlement, including improved out‑of‑area expense settlement
- Compliance Requirements: Designated medical institutions and pharmacies must enforce real‑name verification for consultations and drug purchases and deliver care consistent with treatment standards
- Supervision: Integrated oversight by people’s congresses, government departments, and the public; dynamic, intelligent fund monitoring; strengthened legal liabilities and increased penalties for violations
Market Impact & Outlook
- Policy Certainty: Elevating medical security rules to statutory level provides a durable, predictable framework for hospitals, insurers, and pharmaceutical companies operating in China
- Procurement Pressure Persists: Codification of centralized procurement for drugs and consumables signals continued price pressure — and volume opportunity — across the pharma and medtech supply chain
- Payer Reform Accelerates: Composite and diversified payment methods, combined with direct settlement, should streamline reimbursement and shift bargaining power toward payers in collective negotiations
- Commercial Insurance Tailwind: Explicit state encouragement of commercial health insurance and mutual aid opens growth headroom for private insurers supplementing the basic system
- Compliance Costs Rise: Real‑name verification mandates and enhanced fund monitoring with stricter penalties will raise compliance standards for designated providers and pharmacies ahead of the 2027 effective date
Forward‑Looking Statements — This brief contains forward-looking assessments of policy implementation, market structure, and industry impact that involve risks and uncertainties. Actual outcomes may differ materially. Nothing herein constitutes investment advice.-Fineline Info & Tech